A recent study indicates that patients who stop using new weight-loss injections like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a major health publication demonstrates that while obese people often shed about a fifth of their body weight while on the medication, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these drugs should be aware of the potential of fast rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting mass within about a year and a half.
Comparing Approaches
The analysis, which examined dozens of trials involving thousands of participants, compared the effects of these new drugs with other pills.
The team point out that individuals who shed pounds through lifestyle changes alone usually have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Experts propose the mode of action of the drugs accounts for the amplified regain.
The injections copy a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in appetite is unsuppressed, making excessive eating much more probable."
A Chronic Condition?
The NHS suggest the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals contend that, considering the high risk of relapse, the treatment should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who state that the results "emphasize the long-term nature of obesity," akin to managing diseases like hypertension.
Patient Experiences
Individuals who have stopped the medication report a powerful resurgence of hunger.
"It felt as if a trigger that goes on and you're instantly extremely hungry," recalled one woman.
This difficulty is compounded if patients have not adopted sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Figures suggest that millions of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent solution and long-term success hinges on combined lifestyle management.
